Recruiting
Early Phase 1

MITI-001

Sponsor:

Stanford University

Code:

NCT07238790

Conditions

IBS (Irritable Bowel Syndrome)

Diarrhea

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

MITI-001 administration

Study Details

Brief summary:

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms.

MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Conditions

IBS (Irritable Bowel Syndrome)

Diarrhea

Study ID

NCT07238790

Start date

Mar 10, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 18 to 65 inclusive at the time of signing the informed consent
2. Diagnosis of IBS-D according to the Rome IV criteria
3. At least 1 of the following measures of microbiome dysfunction:

1. Primary bile acid proportion greater than or equal 10% in stool samples, or
2. Positive hydrogen breath test (with either glucose or lactulose substrate)
3. Stool Enterobacteriaceae > 1% relative abundance within 60 days of screening visit
4. Normal C-reactive protein level
5. Gallbladder intact
6. Willing to use appropriate contraception during the treatment period and for one week after the last study visit.
7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
8. Able to tolerate the planned course of antibiotics, EGD, and colonoscopy with bowel lavage.

Exclusion Criteria:

1. IBD
2. Untreated enteric infections
3. History of GI surgery: All participants with GI surgeries below the pylorus will be excluded from this study. This includes participants with a history of colectomy, segmental colonic resection, and small bowel resections.
4. Documented severe gastroparesis
5. Active intestinal obstruction
6. Dysphagia (oropharyngeal, esophageal, functional, or neuromuscular)
7. History of recurrent aspiration episodes
8. Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy/bleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery
9. Active symptoms of major depressive disorder (PHQ-9 score >15)
10. Severe immunodeficiency, inherited or acquired
11. Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator
12. Active antibiotic use (except protocol-specified antibiotics)
13. Active treatment with high levels of immunosuppressive therapies (active chemo or immunosuppressive meds \[steroids, biologic therapies, bone marrow suppressive agents\], radiation therapy)
14. Active anticoagulant or antiplatelet therapy, or use of other medications associated with a high risk of bleeding within 48 hours prior to endoscopy on Day 1
15. Active opiate use
16. Simultaneous participation in aother interventional clinical trial
17. Renal insufficiency (eGFR < 50mL/min)
18. Absolute neutrophil count <1000 microL, platelet count < 50 x 10\^9/L, or hemoglobin <6.5 g/dL
19. Pregnant, breastfeeding, or planning pregnancy during study period
20. Active drug or alcohol use disorder
21. Known allergy or anaphalaxyis to vancomycin, metronidazole, ciprofloaxin, polyethylene glycol, meropenem, amoxicillin/clavulanate potassium, or piperacillin/tazobactam
22. Inability to comply with research requirements

Study Design

Enrollment

13 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intervention arm (MITI-001)

Dosed with MITI-001

Interventions

MITI-001 administration

A complex gut bacterial community (MITI-001) will be given endoscopically and orally

Primary outcome measure

  • Determine the safety of MITI-001 in the participant population [ Time Frame: up to 90 days ]

Central Contacts and Locations

Central contacts

Sean Spencer, Assistant Professor of Medicine, MD, PhD

6507365555seanspen@stanford.edu

Aubrey Adiao, Clinical Research Coordinator

aadiao@stanford.edu

Locations

Stanford Digestive Health Clinic

Recruiting

Redwood City, California, United States, 94063

Contacts

Linda Nguyen, MD

(650) 736-5555

Stanford University

Recruiting

Stanford, California, United States, 94305

Contacts

More Information

Sponsor

Stanford University

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • IBS with Diarrhea Predominance (IBS-D)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.